Citra ph

Citra ph Medicine

Overdose

As with all antacids, overdose may produce metabolic alkalosis. The product contains 27mmol of Sodium ions per 30ml and this should be considered. Management of overdose should include monitoring of plasma electrolytes and acid-base status, and general supportive measures.

Contraindications

Hypersensitivity to the active ingredient or to other ingredients of the product.

Incompatibilities

Not applicable

Undesirable effects

4, 4.5 and 4.9 of the Summary of Product Characteristics.

Preclinical safety data

No further data is provided.

Therapeutic indications

Non-particulate antacid for use by mouth to prior to general anaesthesia for caesarean section.

Pharmacodynamic properties

Citra pH has no relevant pharmacodynamic activity other than that caused by its alkalinity (e.g. its gastric acid neutralising capacity).

Pharmacokinetic properties

Citra pH is systemically absorbed and renally eliminated, causing metabolic alkalosis and urine alkalisation in sufficient doses.

Name of the medicinal product

Citra pH

Qualitative and quantitative composition

Sodium Citrate

Special warnings and precautions for use

Citra pH should not be administered to patients with metabolic or respiratory alkalosis, hypocalcaemia, or hypochlorhydria. Sodium containing salts should be administered extremely cautiously to patients with heart failure, oedema, renal impairment, hypertension, or aldosteronism. (During treatment of acidosis, frequent monitoring of serum-electrolyte concentrations and acid-base status is essential. Alkalinisation of the urine by bicarbonates or bicarbonate precursors leads to increased renal clearance of acidic drugs.) However, urinary alkalinisation prolongs the half-life of basic drugs and may result in toxicity.

Citrates and Citric Acid enhance intestinal aluminium absorption in renal patients which may lead to increased, harmful serum aluminium levels. It has therefore been suggested that patients with renal failure taking aluminium compounds to control phosphate absorption should not be prescribed citrate or citric acid containing products.

Effects on ability to drive and use machines

Not applicable

Dosage (Posology) and method of administration

30ml of a 0.3M solution orally immediately prior to anaesthesia.

Special precautions for disposal and other handling

None